MannKind Company Profile (NASDAQ:MNKD)

About MannKind (NASDAQ:MNKD)

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MNKD
  • CUSIP: 56400P20
  • Web:
  • Market Cap: $153.53 million
  • Outstanding Shares: 101,006,000
Average Prices:
  • 50 Day Moving Avg: $1.12
  • 200 Day Moving Avg: $0.96
  • 52 Week Range: $0.41 - $2.38
  • Trailing P/E Ratio: 1.07
  • Foreward P/E Ratio: -1.90
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $177.77 million
  • Price / Sales: 0.86
  • Book Value: ($2.08) per share
  • Price / Book: -0.73
  • EBIDTA: $65.91 million
  • Return on Equity: -15.95%
  • Return on Assets: 46.57%
  • Debt-to-Equity Ratio: -0.62%
  • Current Ratio: 0.46%
  • Quick Ratio: 0.41%
  • Average Volume: 3.51 million shs.
  • Beta: 3.26
  • Short Ratio: 16.2

Frequently Asked Questions for MannKind (NASDAQ:MNKD)

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08. The business earned $3 million during the quarter, compared to the consensus estimate of $3.50 million. The business's quarterly revenue was up 2900.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) earnings per share. View MannKind's Earnings History.

Where is MannKind's stock going? Where will MannKind's stock price be in 2017?

3 equities research analysts have issued 1-year price targets for MannKind's stock. Their forecasts range from $0.15 to $1.00. On average, they expect MannKind's stock price to reach $0.66 in the next twelve months. View Analyst Ratings for MannKind.

Are investors shorting MannKind?

MannKind saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 23,909,169 shares, an increase of 11.5% from the April 28th total of 21,447,866 shares. Based on an average daily volume of 7,556,248 shares, the days-to-cover ratio is currently 3.2 days. Currently, 43.3% of the company's stock are sold short.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:

  • Kent Kresa, Chairman of the Board
  • Matthew Jonathan Pfeffer CPA., Chief Executive Officer, Chief Financial Officer, Director
  • Rose Alinaya, Senior Vice President, Principal Accounting Officer
  • Linda Adreveno, Senior Vice President - Human Resources
  • Joseph Kocinsky, Chief Technology Officer, Corporate Vice President
  • David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary
  • Michael E. Castagna Pharm.D., Corporate Vice President, Chief Commercial Officer
  • Raymond W. Urbanski M.D., Ph.D., Corporate Vice President, Chief Medical Officer
  • Stuart A. Tross Ph.D., Chief People Officer
  • James Samuel Shannon M.D., Director

Who owns MannKind stock?

MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FLYNN JAMES E (5.17%), Vanguard Group Inc. (3.10%), Morgan Stanley (0.57%), Harel Insurance Investments & Financial Services Ltd. (0.51%), Geode Capital Management LLC (0.50%) and Bank of New York Mellon Corp (0.29%). Company insiders that own MannKind stock include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Institutional Ownership Trends for MannKind.

Who sold MannKind stock? Who is selling MannKind stock?

MannKind's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Harel Insurance Investments & Financial Services Ltd., Geode Capital Management LLC, Morgan Stanley, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC, Wells Fargo & Company MN and Teachers Advisors LLC. View Insider Buying and Selling for MannKind.

Who bought MannKind stock? Who is buying MannKind stock?

MannKind's stock was purchased by a variety of institutional investors in the last quarter, including KCG Holdings Inc.. Company insiders that have bought MannKind stock in the last two years include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Insider Buying and Selling for MannKind.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MannKind stock can currently be purchased for approximately $1.52.

MarketBeat Community Rating for MannKind (NASDAQ MNKD)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MannKind (NASDAQ:MNKD) (?)
Ratings Breakdown: 3 Sell Ratings
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: $0.66 (56.58% downside)

Analysts' Ratings History for MannKind (NASDAQ:MNKD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017JPMorgan Chase & Co.Reiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
5/8/2017S&P Equity ResearchLower Price Target$1.04 -> $0.83HighView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs Group IncReiterated RatingSellN/AView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00N/AView Rating Details
11/14/2015Jefferies Group LLCReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for MannKind (NASDAQ:MNKD)
Earnings by Quarter for MannKind (NASDAQ:MNKD)
Earnings History by Quarter for MannKind (NASDAQ:MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MannKind (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.80 EPS


Dividend History for MannKind (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MannKind (NASDAQ:MNKD)
Insider Ownership Percentage: 0.94%
Institutional Ownership Percentage: 19.71%
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MannKind (NASDAQ:MNKD)
Latest Headlines for MannKind (NASDAQ:MNKD)
DateHeadline logoMannKind Co. (MNKD) Sees Large Growth in Short Interest - May 26 at 7:53 AM logoJPMorgan Chase & Co. Reaffirms Underweight Rating for MannKind Co. (MNKD) - May 22 at 10:54 AM logoReading MannKind's SEC Documents Would Help Investors Preserve Their Capital - Seeking Alpha - May 19 at 11:15 AM logoHealth Care Sector Update for 05/16/2017: MNKD,AKBA,FMS,ETRM - Nasdaq - May 18 at 8:26 AM logoMannKind Co. (MNKD) Earns "Sell" Rating from JPMorgan Chase & Co. - May 13 at 6:26 PM logoMannKind Co. (MNKD) Given a $1.00 Price Target by Piper Jaffray Companies Analysts - May 13 at 6:26 PM logoMannKind Corp.: Nothing But Losses - Seeking Alpha - May 12 at 7:12 PM logoMannKind Reports Q1 Loss - What Investors Need To Know - Seeking Alpha - May 11 at 7:05 PM logoImplied Volatility Surging for MannKind Corporation (MNKD) Stock Options - Nasdaq - May 11 at 7:05 PM logoImplied Volatility Surging for MannKind Corporation (MNKD) Stock Options - May 11 at 7:05 PM logoHere's Why MannKind Corporation Stock Is Tanking Today - May 11 at 7:05 PM logoHere's Why MannKind Corporation Stock Is Tanking Today - May 11 at 4:16 PM logoMannKind Corporation (MNKD) Stock Slammed Despite Smaller Q1 Losses - May 11 at 11:43 AM logoMannKind Q1 revenue disappoints, shares down 15% - May 11 at 11:20 AM logoMannKind's (MNKD) CEO Matthew Pfeffer on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 11 at 7:00 AM logoEdited Transcript of MNKD earnings conference call or presentation 10-May-17 9:00pm GMT - May 11 at 6:59 AM logoMannKind Co. (MNKD) Announces Quarterly Earnings Results, Misses Estimates By $0.29 EPS - May 10 at 11:48 PM logo10-Q: MANNKIND CORP - May 10 at 6:41 PM logoMannKind Corporation Reports 2017 First Quarter Financial Results - May 10 at 6:41 PM logoMannKind reports 1Q loss - May 10 at 6:41 PM logoMannKind Corporation (MNKD) Shares Continue to Surge on ‘One Drop’ News - May 10 at 1:20 PM logoMannKind Corporation (MNKD) Shares Continue to Surge on ‘One Drop’ News - May 10 at 1:10 PM logoInvestor Network: MannKind Corporation to Host Earnings Call - May 10 at 12:20 PM logoMannKind Co. (MNKD) Price Target Cut to $0.83 by Analysts at S&P Equity Research - May 8 at 4:16 PM logoMannKind: Afrezza Sales Still Low As Company Tries To Increase ... - Seeking Alpha - May 5 at 6:52 PM logoMannKind (MNKD) Given Daily News Impact Rating of -0.02 - May 4 at 7:24 PM logoMannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes - May 4 at 11:37 AM logoMannKind Hopes To Reverse Fortunes With Television Show - Seeking Alpha - May 3 at 8:02 AM logoSomewhat Positive Press Coverage Very Likely to Affect MannKind (MNKD) Share Price - May 1 at 7:56 PM logoMannKind (MNKD) Getting Somewhat Favorable Media Coverage, Report Shows - April 29 at 12:20 AM logoMannKind Corporation to Hold 2017 First Quarter Financial Results Conference Call on May 10, 2017 - April 28 at 9:13 AM logoMannKind Co. (MNKD) Short Interest Up 10.7% in April - April 27 at 7:10 AM logoFavorable Press Coverage Likely to Affect MannKind (MNKD) Stock Price - April 25 at 8:14 PM logo$0.12 EPS Expected for MannKind Co. (MNKD) This Quarter - April 25 at 12:26 AM logoMannKind (MNKD) Earns Coverage Optimism Score of 0.09 - April 21 at 9:54 PM logoMannKind Co. (MNKD) Short Interest Update - April 19 at 6:56 PM logoBRIEF-Mannkind's unit entered exchange agreement - April 19 at 10:31 AM logoSomewhat Positive Press Coverage Very Likely to Impact MannKind (MNKD) Share Price - April 18 at 6:05 PM logoVery Favorable News Coverage Very Likely to Impact MannKind (MNKD) Share Price - April 14 at 10:54 AM logoIs MannKind Corporation Getting Ready to Sell? - April 10 at 4:50 PM logoConatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand - April 3 at 10:12 AM logoShort Interest in MannKind Co. (MNKD) Declines By 5.9% - March 27 at 7:47 AM logoMANNKIND CORP Financials - March 23 at 7:07 PM logoBillionaires' Worst Healthcare Stock Picks for 2017 (So Far) - March 22 at 9:25 AM logoCould MannKind Corporation's Marketing Blitz Pay Off? - March 21 at 4:25 PM logoJefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now - March 20 at 10:12 AM logoEdited Transcript of MNKD earnings conference call or presentation 16-Mar-17 9:00pm GMT - March 17 at 6:45 PM logoMANNKIND CORP Files SEC form 8-K, Other Events - March 17 at 6:45 PM logoMannKind Co. (MNKD) Issues Quarterly Earnings Results - March 16 at 10:21 PM logo10-K: MANNKIND CORP - March 16 at 7:19 PM



MannKind (MNKD) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff